Oxford Nanopore Technologies Plc develops proprietary technology platform for the electronic analysis of single molecules. The firm has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
Oxford Nanopore Technologies PLC의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Oxford Nanopore Technologies PLC 주요 수익원은 Life Science Research Tools이며, 최신 수익 발표에서 수익은 169,668,000입니다. 지역별로는 Europe, Middle East, Africa, and India이 Oxford Nanopore Technologies PLC의 주요 시장이며, 수익은 74,037,000입니다.
Oxford Nanopore Technologies PLC은 수익성이 있나요?
no, 최신 재무제표에 따르면 Oxford Nanopore Technologies PLC의 순손실은 $-145입니다.
Oxford Nanopore Technologies PLC에 부채가 있나요?
예, Oxford Nanopore Technologies PLC의 부채는 159입니다.
Oxford Nanopore Technologies PLC의 발행 주식은 몇 주인가요?
Oxford Nanopore Technologies PLC의 총 발행 주식은 966.05주입니다.